The FDA has granted its final approval to the first neurostimulation device designed to treat the symptoms of heart failure. Cvrx Inc.'s Barostim Neo system received premarket approval on Friday for the improvement of symptoms in patients with advanced heart failure who are not eligible for treatment with cardiac resynchronization therapy or other heart failure devices. Read More
